Antibe Therapeutics Inc.
ATE
Clasificación en acciones
#31891
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Precio por acción
$0.21483059
Última sincronización: 2024-05-07
Capitalización bursátil
$11.13M
Cambio (1 día)
0.34%
Cambio (1 año)
-0.36%
País
CA
Comercio Antibe Therapeutics Inc. (ATE)
Categoría
Healthcare
Ratio P/S de Antibe Therapeutics Inc. (ATE)
Ratio P/S al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Antibe Therapeutics Inc., el ratio P/S actual (TTM) es 0. Al final de 2026, el ratio P/S era 0.
Historial del ratio P/S de Antibe Therapeutics Inc. desde 2026 hasta 2026
Ratio P/S al final de cada año
| Año | Ratio P/S | Cambiar |
|---|---|---|
| Not enough data for the provided dates. | ||
Ratio P/S de empresas similares o competidoras
| Empresa | Ratio P/S | Diferencia del ratio P/S | País |
|---|---|---|---|
| 3.82 | - |
US
|
|
| 2.78 | - |
IE
|
|
| 4.18 | - |
US
|
|
| 2.97 | - |
US
|
|
| - | - |
DE
|
